NCT02823327

Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 25 (actual)
• Sponsor: AIDS Malignancy Consortium · Network
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This research trial studies clinical factors and gene expression analysis for prognosis in tissue samples from patients with acquired immune deficiency syndrome (AIDS)-related primary effusion lymphoma. Gathering health information over time and studying samples of tissue from patients in the laboratory may help doctors learn about the prognosis of patients with AIDS-related primary effusion lymphoma.

Detailed description

PRIMARY OBJECTIVES: I. Identify baseline clinical characteristics and treatment strategies in patients with AIDS-associated primary effusion lymphoma (PEL) that correlate with long-term survival (\>= 2 years). (Primary clinical objective) II. Identify differentially expressed genes in PEL that are associated with long-term survival (\>= 2 years). (Primary genomic objective) OUTLINE: Medical chart review is performed and patient information is collected regarding human immunodeficiency virus human immunodeficiency virus (HIV)/AIDS medical history, staging of AIDS related malignancy, and type of treatment. Previously collected tissue samples are analyzed via ribonucleic acid (RNA) sequencing and microarray.

Conditions

• AIDS-Related Primary Effusion Lymphoma

Interventions

Type	Name	Description
GENETIC	Laboratory Biomarker Analysis	Correlative studies
OTHER	Medical Chart Review	Medical chart review is performed

Timeline

• Start date: 2016-10-11
• Primary completion: 2023-02-03
• Completion: 2023-02-03
• First posted: 2016-07-06
• Last updated: 2025-05-11
• Results posted: 2025-05-11

Locations

6 sites across 1 country: United States